Acute lung injury represents a wide spectrum of pathologic processes, the most severe end of the spectrum being the acute respiratory distress syndrome. Reactive oxygen intermediates have been implicated as important in the pathobiochemistry of acute lung injury. The endogenous sources that contribute to the generation of reactive oxygen intermediates in acute lung injury are poorly defined but probably include the molybdenum hydroxylases, NAD(P)H oxidoreductases, the mitochondrial electron transport chain, and arachidonic acid-metabolizing enzymes. Our laboratory has focused, in particular, on the regulation of two of these enzyme systems, xanthine oxidoreductase (XDH/XO) and NAD(P)H oxidase. We observe that gene expression of XDH,XO is regulated in a cell-specific manner and is markedly affected by inflammatory cytokines, steroids, and physiologic events such as hypoxia. Posttranslational processing is also important in regulating XDH/XO activity. More recently, the laboratory has characterized an NAD(P)H oxidase in vascular cells. The cytochrome components of the oxidase, gp91 and p22, appear similar to the components present in phagocytic cells that contribute to their respiratory burst. In human vascular endothelial and smooth muscle cells, oncostatin M potently induces gp91 expression. We believe that regulation of gp91 is a central controlling factor in expression of the vascular NAD(P)H oxidase. In summary, the studies support the concept that the oxidoreductases of vascular cells are expressed in a highly regulated and self-specific fashion. Environ Health Perspect 1 06(Suppl 5):1 235-1239 (1998). http.//ehpnetl.niehs.nih.gov/docs/1998/Suppl-5/ 1235-1239hoidal/abstract.html
effective therapies or prophylactic measures to decrease the incidence and severity of this devastating disorder.
Oxidants and Acute Lung Injury
A number of independent pathogenic mechanisms may cause acute lung injury. One group of inorganic compounds with a high degree of chemical reactivity that has been implicated is the reactive oxygen intermediates (ROI), including superoxide anion radical (02-, hydrogen peroxide (H202), hydroxyl radical, and products of myeloperoxidase. ARDS patients have increased production of oxidants in their lungs, as indicated by an increased concentration of H202 in expired air (3) , and a deficiency in alveolar epithelial lining fluid glutathione with a greater percentage in the oxidized form (4) . In addition, some of the detrimental effects of ROI are mediated through the reaction of 02 --with nitric oxide to form the potent oxidant OONO-. Potentially toxic levels of OONO-are present in the lungs ofARDS patients (5) .
Animal models provide strong support for the critical involvement of oxidants in acute lung injury. The role has been demonstrated in models of lung injury from sepsis (6) , viral pneumonia (7), ischemia-reperfusion (8) , hemorrhagic shock, a systemic ischemia-reperfusion insult (9) , and hyperoxia (10) . Antioxidant enzymes or scavengers markedly reduce the lung injury in these models.
Several mechanisms have been identified by which oxidants can cause lung dysfunction. Oxidants react with many cellular components, oxidizing proteins, lipids, DNA bases, enzymes for intermediary metabolism, and extracellular matrix components including collagen and hyaluronic acid (11) (12) (13) . The production of PGI2, isoprostanes,-and lipoxygenase products is altered, causing defects in platelet aggregation and vasorelaxation (14, 15) . Depending on the extent of oxidant stress, cells exposed to ROI will undergo apoptosis or necrosis (16) . In endothelial and epithelial cells, oxidant injury may also impair macromolecular barrier function, which leads to pulmonary edema (17) . As (19) or can increase leukocyte adhesion to endothelium via activation of nuclear factor-kappa B-mediated transcription of integrin genes (20, 21 (23) , and following sepsis (24) or hemorrhagic shock (25) .
Sources of XDH/XO that mediate injury include resident lung cells such as endothelial and epithelial cells, both important sources of the enzyme in some species (26, 27) . Additionally, diverse pathologic processes result in circulating XDH/XO. XDH/XO released from tissues into plasma can bind to sulfated glycosoaminoglycans on vascular endothelial cells to produce site-specific oxidant injury to organs remote from the site of release (28) . As one example, XDH/XO-rich effluent from reperfused ischemic liver accumulates in the lung in an enzymatically active form (29) . Importantly, patients with ARDS (3), viral infections (30), or tourniquet-related ischemia-reperfusion injury have markedly increased levels of plasma XDH/XO (31). These (40) . These findings suggest an alternative mechanism for ischemia-induced reperfusion injury. By this alternative mechanism, ischemia elevates intracellular NADH levels, which leads to 02-generation by XDH/XO on reoxygenation of tissues. This mechanism does not depend on XDH-to-XO conversion (a controversial issue). We believe that the NADH oxidation does not involve the molybdenum center of the enzyme (Figure 1) During the past few years, evidence has been accumulating that a similar enzyme complex is present and exerts a variety of functions in nonphagocytic cells. Both the icture and endothelium and vascular smooth muscle dase comes contain a membrane-bound oxidase that hils in which uses NADH and NADPH as substrates for ie respiratory electron transfer to 02 that appears similar ;idal activity to the NAD(P)H oxidase of neutrophils se is a multi- (44) (45) (46) . In cultured vascular smooth ites O2-in muscle cells, the oxidase is a significant using elec-source of O2 --formation (47) . For exam-[reviewed by ple, in calf pulmonary and coronary artery expressed at smooth muscle, this oxidase accounts for eO2 is the the majority of the 02--generated her reactive (45, 48) . Importantly, it uses a cytochrome l and fungi. b558 electron transport system (45) . There mbrane pro-are, however, important differences ether form a between the vascular oxidase and the neuox midpoint trophil oxidase. These include the delayed duced minus time course for activation, low output, and f 558. Based in some studies, the preference for NADH mnic granulo-rather that NADPH of the vascular oxitwo cystolic dase. The low-output property does not [so essential. detract from the importance of the vascuPonents that lar oxidase as an initiator of endothelial or -tivity of the smooth muscle dysfunction, and it may e have been function as a signaling system for gene [ 1 G (46) , but this has not been a consistent finding (51). Because the substrate specificity of the neutrophil NAD(P)H oxidase resides in gp91, it is likely that it is this subunit that determines the unique properties of the vascular oxidase.
To define the components responsible for the NAD(P)H oxidase activity in human vascular cells, we screened a human umbilical vein endothelial cell (HUVEC) cDNA library (in lgt 1l; Clontech, Palo Alto, CA) using probes for gp91, p22, p47, and p67. The probes were generated by polymerase chain reaction using primers designed from phagocyte sequences. To date we have isolated from the HUVEC library a full-length p22 cDNA, a 1200-bp fragment of gp91, and a 500-bp fragment of p67. We have also amplified by reverse transcriptase-polymerase chain reaction (RT-PCR) a 350-bp fragment from HUVEC mRNA using primers specific for p47 but have not as yet isolated a p47 clone by library screening. These fragments have been sequenced and are identical to their neutrophil counterparts. Likewise, in fragments derived from pulmonary artery smooth muscle cells (PASMC) by RT-PCR, we have sequenced approximately 300 bp from the translated region of p22, p47, and p67, and, as in the case of endothelial cells, the sequences are identical to their phagocytic counterparts.
To initiate studies to define the factors that determine cell-specific gene expression, we used RT-PCR to identify transcripts for the NAD(P)H oxidase components in isolated endothelial and vascular smooth muscle cells. We neither induced gp91 gene expression in HUVEC or PASMC nor changed the level of mRNA transcripts for the other three components. However, oncostatin M (OSM) potently induced gp91 in HUVEC and PASMC. The induction of gp91 required 8-to 24-hr exposure to OSM and was blocked by addition of cycloheximide (5 pg/ml), suggesting a requirement for intermediate protein synthesis. At variance with the induction of mRNA transcripts for gp91 by OSM, there was no induction of the other NAD(P)H oxidase components by any of the cytokines. This suggests that whereas gp91 is inducible in HUVEC and PASMC, p22, p47, and p67 are constitutively expressed in these cells. On the basis of these findings, we propose that regulation of gp91 is a central controlling factor in the expression of the vascular NAD(P)H oxidase.
In summary, recent studies support the concept that the oxidoreductases of vascular cells are expressed in a highly regulated and cell-specific fashion. The regulation of these enzyme systems is likely to have a profound impact on their role in acute lung injury.
